Valeant Tumbles on Earnings Woes

Valeant Pharmaceuticals (VRX) was plummeting in morning trading Tuesday, with more than a quarter of the debt-laden drugmaker's market cap vanishing before the opening bell on a disastrous earnings rollout.

Shares of Valeant were down more than 20% at $14.95 a share in early trading after the struggling Canadian drugmaker posted third-quarter earnings far below consensus estimates, compounded by cuts to its guidance for the remainder of the year -- putting Valeant at risk of breaching covenants on some of its roughly $31 billion of debt.

Earnings clocked in at $1.55 a share for the third quarter, below average analyst expectations of $1.76, while sales of $2.48 billion for the period fell short of the $2.52 billion predicted. Valeant also slashed its earnings guidance to a range of $5.30 to $5.50 a share for the year, from a previous range of $6.60 to $7.

"We can't change the things in the past; we can only deal with them and change our future," Valeant's newly appointed CFO Paul Herendeen said on Tuesday morning's earnings call with analysts. "We are a new team, and we need to earn your trust. We will do that by being a good corporate citizen, by delivering on our commitments and by being transparent in our financial reporting."

Valeant stock fell by more than 25% at one point in premarket trading, although it recovered somewhat once the market actually opened. But all told, Valeant shares are down about 86% so far this year amid controversy surrounding alleged accounting problems and steep price hikes on products the firm acquired during years of debt-fueled acquisitions. The scandals led to the departure of Chairman and CEO J. Michael Pearson and CFO Howard Schiller from Valeant, which is a member of our "Stressed Out" list of stocks that face big debt pressures.

If you liked this article you might like

ADP Is Morphing Into the IBM Blob: Bill Ackman

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year